Health ministry mulled compulsory licencing of rare disease drugs

NEW DELHI: The health ministry was actively mulling compulsory licensing, apart from price capping, of “orphan drugs” (for rare diseases), when the department of pharmaceuticals abruptly issued an order exempting such medicines from price control, derailing plans to make these drugs affordable.

The health ministry discussed price capping and invoking compulsory licence for these “exorbitantly” priced “orphan drugs” at a meeting on January 3, the day when DoP issued its order notifying changes to drug price regulation and removing price caps from several essential medicines, including patented and “orphan drugs”.

In fact, even before the meeting, health secretary Preeti Sudan wrote to the department of industrial policy and promotion (DIPP) urging “to explore the feasibility of bringing drugs used for treatment of rare diseases under compulsory licensing so that their costs become affordable to patients”.

TOI had reported on Saturday that the health ministry had also raised similar concerns about high prices of “orphan drugs” and the issue of their unaffordability with pharma secretary Jai Priye Prakash. Despite this, department of pharmaceuticals moved to exempt patented and “orphan drugs” from price control.

“The decision reveals a deep discordance between various arms of the government — the health ministry which is charged with safeguarding health of the public and the DoP which oversees pricing. Because of the serious negative impact, this decision will reduce accessibility to highly priced drugs ,” All India Drug Action Network co-convenor Malini Aisola said.

A compulsory licence is a provision under the Indian Patent Act which allows the government to mandate a generic drug-maker to produce inexpensive medicine in public interest even as a patent on the product is valid.

India has issued only one compulsory licence so far for a cancer drug.

  • Related Posts

    • Pharma
    • May 10, 2025
    • 82 views
    Pharma sector continues to thrive, driven by price-led expansion

    The Indian pharmaceutical market continued rising in April 2025, achieving a strong annual growth of 7.8%, with total sales reaching a remarkable Rs 19,711 crore. According to a report by…

    • Pharma
    • May 10, 2025
    • 78 views
    TPG to acquire 35% stake in SCHOTT Poonawalla from SII

    Mumbai:  SCHOTT Pharma has announced that TPG, a global alternative asset management firm, has entered into a binding agreement to acquire a 35% stake in its joint venture SCHOTT Poonawalla…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Pharma sector continues to thrive, driven by price-led expansion

    Pharma sector continues to thrive, driven by price-led expansion

    TPG to acquire 35% stake in SCHOTT Poonawalla from SII

    TPG to acquire 35% stake in SCHOTT Poonawalla from SII

    Indian pharma industry showed impressive growth in April 2025, by price led expansion: Report

    Indian pharma industry showed impressive growth in April 2025, by price led expansion: Report

    Diabetes drug shows promise for treating prostate cancer

    Diabetes drug shows promise for treating prostate cancer